Project Grant R37CA317177
Award Date 6/22/26
Completion Date 5/31/31
Dollars Obligated $641K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- Summary of Federal Project Grant Award Award Details: The National Cancer Institute (NCI) awarded $157,000 in project grant funding (CFDA 93.395, Cancer Treatment Research) to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, effective July 1, 2026, through June 30, 2028. The research will be conducted in Cleveland, Ohio. Products and Services: This project grant supports research to identify and characterize gut bacterial species that can modulate immune checkpoint...
- Federal Project Grant Award Summary The National Cancer Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a Project Grant of $713,601 (awarded August 1, 2025; completion date July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to investigate how homologous recombination (HR) DNA repair pathway mutations influence tumor immunity and immunotherapy efficacy. The research will characterize the mechanisms by which HR defects affect...
- Federal Project Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $442,750 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) for the period July 1, 2025 through June 30, 2027. The award funds research to systematically identify drivers controlling interactions between Fusobacterium nucleatum (FN), a bacterium commonly found in oral...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $669,278 to the University of Michigan's Office of Research and Sponsored Projects, effective June 1, 2026 through May 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This Multi-Principal Investigator (MPI) R01 application, aligned with PAR-25-107 (Advancing Microbial-Based Cancer Therapy), supports the development of engineered nonpathogenic tumor-tropic E. coli bacteria...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $742,382 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026 through May 31, 2031. The award supports preclinical research to investigate combination immunotherapy approaches for head and neck squamous cell carcinoma (HNSCC), a deadly malignancy with limited treatment options and poor response rates to current checkpoint...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $660,541 to The University of Texas MD Anderson Cancer Center for research under the Cancer Biology Research program (CFDA 93.396). The award, effective April 1, 2026, through March 31, 2031, supports fundamental research on the modulation of the tumor microenvironment by Fusobacterium nucleatum (FN) and co-infecting microbial species in colorectal cancer (CRC). The research addresses a critical...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $443,564 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion by August 31, 2027. The award supports the development of a novel cancer immunotherapy platform utilizing engineered commensal skin bacteria to stimulate tumor-specific T cell immunity. The research focuses on leveraging Staphylococcus epidermidis, a naturally...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $2.86 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a novel microbial-based therapeutic strategy targeting colibactin, a carcinogenic metabolite produced by pathogenic gut bacteria associated with colorectal cancer (CRC). The project, which commenced September 10, 2025, and extends through August 31, 2029, focuses on engineering...
- Federal Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $487,468 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2030. The award supports fundamental research investigating the role of palmitoylation—a reversible lipid modification process—in melanoma lung metastasis and tumor progression. The research will examine how the...
- Federal Grant Award Summary The National Cancer Institute awarded a $1.96M Project Grant (CFDA 93.396, Cancer Biology Research) to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on September 22, 2025, with a completion date of June 30, 2030. The award funds fundamental research investigating the role of V-domain Ig suppressor of T cell activation (VISTA), a next-generation immune checkpoint receptor, in driving immune evasion in acute myeloid leukemia (AML)....